Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493597 | 0.91 | HRH3 (0.60) | HRH3GLAL3MBTL1MAOBALDH1A1 | |
| SCHEMBL5106634 | 0.90 | GLA (0.73) | HRH3GLAL3MBTL1MAOBPOLB | |
| SCHEMBL4622140 | 0.87 | HRH3 (0.66) | HRH3GLAL3MBTL1POLB | |
| SCHEMBL4622753 | 0.87 | HRH3 (0.66) | HRH3GLAL3MBTL1MAOBPOLB | |
| SCHEMBL4486761 | 0.86 | HRH3 (0.65) | HRH3POLBSLC2A1KDM4EALDH1A1 | |
| SCHEMBL14287848 | 0.85 | HRH3 (0.66) | HRH3GLAL3MBTL1MAOBPOLB | |
| SCHEMBL4495437 | 0.84 | HRH3 (0.69) | HRH3GLAL3MBTL1MAOB | |
| Oxalic Acid SCHEMBL4506368 | 0.84 | HRH3 (0.62) | HRH3GLAL3MBTL1POLBKDM4E | |
| Oxalic Acid SCHEMBL4489113 | 0.84 | HRH3 (0.62) | HRH3GLAL3MBTL1POLBKDM4E | |
| SCHEMBL11757419 | 0.84 | HRH3 (0.64) | HRH3GLAL3MBTL1MAOBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576120-B2 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2009-08-18 | — | — | US | disclosed |
| EP-1720544-B1 | NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2008-03-19 | — | — | EP | disclosed |
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | LES LABORATORATIES SERVIER (FR) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197625-A1 | Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. | HRH2, HNMT, HRH1 | HRH3 9/4885GLA 3973/4885L3MBTL1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.